Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.

C. Fieschi, C. Pozzilli, S. Bastianello, T. Koudriavtseva, C. Gasperini, A. Bozzao, S. Galgani, A. Paolillo, E. Millefiorini, C. Buttinelli

Research output: Contribution to journalArticle

Abstract

An open comparative, randomized trial with recombinant human interferon beta (r-hIFN-beta) involving 72 patients with clinically definite and/or laboratory-supported relapsing-remitting MS is in progress at the University 'La Sapienza' and at the S. Camillo Hospital of Rome. After a 6 month period of clinical and magnetic resonance imaging (MRI) observation (baseline findings), patients are randomly assigned to one of two treatment groups receiving 3 or 9 MIU of recombinant human IFN-beta (r-hIFN-beta) self-administered by subcutaneous injection three times a week for 6 months. All patients are examined by MRI with and without gadolinium (Gd-DTPA) every 4 weeks for the entire duration of the study (12 months). The main aim of the study is to test the hypothesis that r-hIFN-beta may halt or slow the progression of the disease by showing a significant reduction in MRI activity. This will be achieved by comparing pre and post-treatment periods. As an additional clinical end point, the exacerbation rate during these two periods will be compared. This study began in June 1993 and the final analysis of MRI data is planned for the spring of 1995.

Original languageEnglish
JournalMultiple Sclerosis Journal
Volume1 Suppl 1
Publication statusPublished - 1995

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Interferon-beta
Magnetic Resonance Imaging
Gadolinium DTPA
Subcutaneous Injections
Therapeutics
Disease Progression
Observation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis : preliminary observations. / Fieschi, C.; Pozzilli, C.; Bastianello, S.; Koudriavtseva, T.; Gasperini, C.; Bozzao, A.; Galgani, S.; Paolillo, A.; Millefiorini, E.; Buttinelli, C.

In: Multiple Sclerosis Journal, Vol. 1 Suppl 1, 1995.

Research output: Contribution to journalArticle

Fieschi, C, Pozzilli, C, Bastianello, S, Koudriavtseva, T, Gasperini, C, Bozzao, A, Galgani, S, Paolillo, A, Millefiorini, E & Buttinelli, C 1995, 'Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.', Multiple Sclerosis Journal, vol. 1 Suppl 1.
Fieschi, C. ; Pozzilli, C. ; Bastianello, S. ; Koudriavtseva, T. ; Gasperini, C. ; Bozzao, A. ; Galgani, S. ; Paolillo, A. ; Millefiorini, E. ; Buttinelli, C. / Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis : preliminary observations. In: Multiple Sclerosis Journal. 1995 ; Vol. 1 Suppl 1.
@article{4278f4d95ca04dc99a78a236196a3596,
title = "Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.",
abstract = "An open comparative, randomized trial with recombinant human interferon beta (r-hIFN-beta) involving 72 patients with clinically definite and/or laboratory-supported relapsing-remitting MS is in progress at the University 'La Sapienza' and at the S. Camillo Hospital of Rome. After a 6 month period of clinical and magnetic resonance imaging (MRI) observation (baseline findings), patients are randomly assigned to one of two treatment groups receiving 3 or 9 MIU of recombinant human IFN-beta (r-hIFN-beta) self-administered by subcutaneous injection three times a week for 6 months. All patients are examined by MRI with and without gadolinium (Gd-DTPA) every 4 weeks for the entire duration of the study (12 months). The main aim of the study is to test the hypothesis that r-hIFN-beta may halt or slow the progression of the disease by showing a significant reduction in MRI activity. This will be achieved by comparing pre and post-treatment periods. As an additional clinical end point, the exacerbation rate during these two periods will be compared. This study began in June 1993 and the final analysis of MRI data is planned for the spring of 1995.",
author = "C. Fieschi and C. Pozzilli and S. Bastianello and T. Koudriavtseva and C. Gasperini and A. Bozzao and S. Galgani and A. Paolillo and E. Millefiorini and C. Buttinelli",
year = "1995",
language = "English",
volume = "1 Suppl 1",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis

T2 - preliminary observations.

AU - Fieschi, C.

AU - Pozzilli, C.

AU - Bastianello, S.

AU - Koudriavtseva, T.

AU - Gasperini, C.

AU - Bozzao, A.

AU - Galgani, S.

AU - Paolillo, A.

AU - Millefiorini, E.

AU - Buttinelli, C.

PY - 1995

Y1 - 1995

N2 - An open comparative, randomized trial with recombinant human interferon beta (r-hIFN-beta) involving 72 patients with clinically definite and/or laboratory-supported relapsing-remitting MS is in progress at the University 'La Sapienza' and at the S. Camillo Hospital of Rome. After a 6 month period of clinical and magnetic resonance imaging (MRI) observation (baseline findings), patients are randomly assigned to one of two treatment groups receiving 3 or 9 MIU of recombinant human IFN-beta (r-hIFN-beta) self-administered by subcutaneous injection three times a week for 6 months. All patients are examined by MRI with and without gadolinium (Gd-DTPA) every 4 weeks for the entire duration of the study (12 months). The main aim of the study is to test the hypothesis that r-hIFN-beta may halt or slow the progression of the disease by showing a significant reduction in MRI activity. This will be achieved by comparing pre and post-treatment periods. As an additional clinical end point, the exacerbation rate during these two periods will be compared. This study began in June 1993 and the final analysis of MRI data is planned for the spring of 1995.

AB - An open comparative, randomized trial with recombinant human interferon beta (r-hIFN-beta) involving 72 patients with clinically definite and/or laboratory-supported relapsing-remitting MS is in progress at the University 'La Sapienza' and at the S. Camillo Hospital of Rome. After a 6 month period of clinical and magnetic resonance imaging (MRI) observation (baseline findings), patients are randomly assigned to one of two treatment groups receiving 3 or 9 MIU of recombinant human IFN-beta (r-hIFN-beta) self-administered by subcutaneous injection three times a week for 6 months. All patients are examined by MRI with and without gadolinium (Gd-DTPA) every 4 weeks for the entire duration of the study (12 months). The main aim of the study is to test the hypothesis that r-hIFN-beta may halt or slow the progression of the disease by showing a significant reduction in MRI activity. This will be achieved by comparing pre and post-treatment periods. As an additional clinical end point, the exacerbation rate during these two periods will be compared. This study began in June 1993 and the final analysis of MRI data is planned for the spring of 1995.

UR - http://www.scopus.com/inward/record.url?scp=0029420601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029420601&partnerID=8YFLogxK

M3 - Article

C2 - 9345395

AN - SCOPUS:0029420601

VL - 1 Suppl 1

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -